€121,- €100,- excl. VAT
Canine Degenerative Myelopathy (DM) is an incurable progressive neurodegenerative disease of the spinal cord.
25 working days
From €5,95 shipping and administration per order (incl. VAT)
Specifications
| Breeds | American Water Spaniel, Borzoi, Glen of Imaal Terrier, Poodle (Standard), Wire Fox Terrier, Airedale Terrier, Komondor, American Eskimo dog, Australian Shepherd, Bernese Mountain dog, Bloodhound, Boxer, Boykin Spaniel, Cardigan Welsh Corgi, Cavalier King Charles Spaniel, Chesapeake Bay Retriever, English Springer Spaniel, German Shepherd, Golden Retriever, Jack Russell Terrier, Kerry Blue Terrier, Labrador Retriever, Nova Scotia Duck Tolling Retriever, Pembroke Welsh Corgi, Pug, Rhodesian Ridgeback, Scottish Deerhound, Shetland Sheepdog, Siberian Husky, Soft Coated Wheaten Terrier |
|---|---|
| Gene | |
| Organ | |
| specimen | Swab, Blood EDTA, Blood Heparin, Semen, Tissue |
| Mode of Inheritance | |
| Chromosome | |
| Also known as | |
| Year Published |
General information
Canine Degenerative Myelopathy (DM) is an incurable progressive neurodegenerative disease of the spinal cord. Neurodegenerative diseases are characterised by progressive loss of neurons in the central nervous system (CNS) which leads to deficiencies in function. In the case of DM, the affected region is the spinal cord, which results in ataxia (a loss of coordination). DM is similar in many ways to Amyotrophic Lateral Sclerosis (ALS) in humans.
This variant of the disease, sometimes designated as SOD1B or as Degenerative Myelopathy Exon 2, occurs in many different breeds. It is probely caused by a autosomal recessive with incomplete penetrance mutation to the gene SOD1. The variant is found in many breeds, but the disease is rarely diagnosed in breeds or in mixed-breed dogs other than those mentioned for this test.
Clinical features
The mutation for DM is present in almost all dog breeds, but in many breeds, it does not cause clinical symptoms. Most dogs that might be affected are at least 5 years of age or older, at the onset of the clinical signs which include reduced strength in the hind legs, incontinence, hyporeflexia, spasticity and ataxia of the pelvic with progression over time to complete paralysis.
Additional information
This test is performed by an external laboratory. CombiBreed takes care of the mediation between you as a customer and the external laboratory. In this case, CombiBreed cannot be held liable for the behaviour of the client and/or contractor.
References
Pubmed ID: 19188595
Omia ID: 263